Focus

• Yima International: sold 3 million shares of China Evergrande New Energy Vehicle through clearance, cashing out HK $11.52 million

IMA International announced on the Hong Kong Stock Exchange that on October 4, 2021, the seller (the company has 90.01% indirect subsidiary Imagi Investments (BVI) Limited) sold 3 million shares of China Evergrande New Energy Vehicle (equivalent to about 0.03% of China Evergrande New Energy Vehicle's issued shares on the date of this announcement) on the open market at an average price of about HK $3.84 per China Evergrande New Energy Vehicle share, for a total consideration of about HK $11.52 million (excluding transaction costs). The company did not hold any shares in China Evergrande New Energy Vehicle after the completion of the sale.

• Hansoh Pharmaceutical Group: the application for listing license of "Pei Hua Xihai Horse Peptide injection" was accepted by the SDA.

Hansoh Pharmaceutical Group announced that the application for listing license of Class 1 innovative drug "Pei Hua Xihai Horse Peptide injection" developed by Jiangsu Hausen Pharmaceutical Group Co., Ltd., a subsidiary of the company, was accepted by the State Drug Administration of the people's Republic of China ("NPMA"). It is intended to be used to treat anemia caused by chronic kidney disease (CKD) and is receiving erythropoietin treatment in dialysis patients.

• Country Garden Holdings: the contract sales amount of shareholders' rights and interests of the company in September reached 45.66 billion yuan.

Country Garden Holdings announced that the contract sales amount of the company and its subsidiaries, together with its joint venture company and associated company, vested in the shareholders' equity of the company is about RMB 45.66 billion in September 2021, and the contract sales floor area vested in the shareholders' equity of the company is about 5.76 million square meters.

• Minimally invasive medical treatment: the acquisition of Hemovent with 88 million euros helps to develop in the field of overall solutions for acute and critically ill cases

Minimally invasive Medical Bulletin, company subsidiary MicroPort Surgical B.V. The acquisition conditions for the acquisition of all issued share capital of Hemovent GmbH from its existing shareholders for a consideration of EUR 88 million have recently been agreed. Upon completion of the transaction, Hemovent will become a wholly owned subsidiary of the Group. In addition, if Hemovent meets certain development milestones and conditions for product development within 5 years from the delivery date, the Group will pay the seller an additional amount up to EUR 35 million. Hemovent was founded in 2013 as a medical device company engaged in innovative extracorporeal life support systems. Hemovent's main products include MOBYBOX, which has been certified by CE and is the first extracorporeal membrane oxygenation system (ECMO) that integrates blood circulation and gas exchange.

• Cetraxal ®Plus has been successfully registered with the Pharmacy and Poisons Board of Hong Kong

Li Da Pharmaceutical Co., Ltd. announced that on October 4, 2021, Lee's wholly owned subsidiary, Li Shi Da Pharmaceutical (Hong Kong) Plus, has launched Laboratorios Salvat,S.A. ("Salvat") licensed ear drops product Cetraxal ®Plus in the Hong Kong market. Cetraxal ®Plus was successfully registered with the Pharmacy and Poisons Board of Hong Kong in December 2020. Cetraxal ®Plus was used to treat acute otitis media and acute otitis media with tympanic membrane catheterization. Phase III clinical trials were carried out in China in January 2021 and a total of 600 subjects are planned to be recruited. To date, 575 targets have been recruited for the plan.

Operation data

Sales of Kaisa Group (01638.HK) in the first nine months were 87.549 billion yuan, an increase of about 32.9% compared with the same period last year.

Sales of Jinhui Holdings (09993.HK) in the first nine months were 73.35 billion yuan, up 19.9% from the same period last year.

Sales of Jingrui Holdings (01862.HK) reached 24.328 billion yuan in the first nine months

Contract sales of 01107.HK rose 24.62% to 33.029 billion yuan in the first nine months compared with the same period last year.

Central Plains Construction Industry (09982.HK) added 996000 square meters of contract construction area in September, an increase of 32.2% over the same period last year.

Resume trading and suspend trading

Alpha Enterprise (00948.HK) won Zhuang Shun and offered to resume trading tomorrow at a premium of about 1.69%.

Increase and decrease holdings

Hu Yiping, Chairman of the Board and a controlling shareholder of the company, increased his stake in 27.646 million shares by 02019.HK.

Sun JH, a controlling shareholder of New Entertainment Holdings (06933.HK), sells 1 million shares of the company

00585.HK: clearance sale of 3 million shares of China Evergrande New Energy Vehicle, cashing out HK $11.52 million

Merger and acquisition and sale

00242.HK Group plans to acquire D shares of Weimar Series for US $70 million

Additional rights issue

Capital Venture Capital (02324.HK) plans to discount about 5.66% to raise HK $16.9 million by placing 68.64 million shares.

Investment and operation

China Water Affairs (00855.HK) signs cooperation agreement with Guizhou Leshui

00112.HK Group: Lettel Business has been ordered to be wound up

Beijing Yiju, a subsidiary of China Creative Holdings (08368.HK), entered into a cooperation framework agreement with Beijing Shuicai Culture Media.

Hyron Holdings (01623.HK) signed a drill pipe supply contract with ADNOC Drilling with a value of US $69 million.

China Environmental Protection Technology (00646.HK) and Zhang Zihong signed a subscription and settlement agreement at a premium of about 96.08% for the allotment of 36.5 million shares.

Zhongsheng Group (00881.HK)'s acquisition of Renfu China shares will be completed at a price of US $1.328 billion.

Ronghui International (00990.HK) issued a written notice to Parker Technology to exercise the option to increase its registered capital to 600 million yuan.

01709.HK develops global identity planning and wealth inheritance consulting services

Repurchase cancellation

XIAOMI Group-W (01810.HK) spent HK $49.45 million to buy back 2.4 million shares on October 4th.

Want Want China (00151.HK) spent HK $17.227 million to buy back 2.996 million shares on October 4th.

Fosun (00656.HK) spent HK $18.875 million to buy back 2 million shares on October 4th.

Jinshan Software (03888.HK) spent HK $9.857 million to buy back 330000 shares on October 4th.

China Gas (00384.HK) spent HK $63.1712 million to buy back 2.9304 million shares on October 4th.

02013.HK Group spent HK $2.627 million to buy back 233000 shares on October 4th.